Peer-reviewed veterinary case report
Nasal shedding of vaccine and field Bordetella in puppies
By Iemura, R et al.·Published in The Veterinary record·2009·Intervet K. K. Central Research Laboratories, Japan·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Simultaneous analysis of the nasal shedding kinetics of field and vaccine strains of Bordetella bronchiseptica.
- Species:
- dog
Plain-English summary
Four two-week-old puppies were given an intranasal vaccine to protect against Bordetella bronchiseptica, which causes kennel cough, and were later exposed to the actual bacteria. The puppies that received the lowest vaccine dose showed some signs of illness and shed the bacteria for two to three weeks, while those that received higher doses either shed it briefly or not at all. No serious side effects were noted from the vaccine, and the vaccinated puppies developed antibodies against the bacteria. This suggests that the vaccine can help protect puppies from kennel cough, but the dose matters for how well it works.
People also search for: puppy kennel cough vaccine · Bordetella bronchiseptica symptoms · puppy vaccination side effects
Abstract
Groups of four two-week-old puppies were administered serial dilutions of an intranasal vaccine containing live Bordetella bronchiseptica and canine parainfluenza virus vaccine and housed individually in isolator cages. Three vaccinated groups and one unvaccinated control group were exposed to virulent B bronchiseptica four weeks after vaccination and evaluated. Nasal swabs for bacterial culture and sera for agglutination tests were taken from all the dogs every week for four weeks. The bacteria isolated were identified by growth on specific agar and by specific PCR to distinguish between vaccine and challenge strains. The vaccine strain persisted in the nasal cavity after vaccination but no adverse reactions were observed. Serum agglutination titres were raised in the vaccinated dogs at challenge. Vaccine strains were not isolated after the challenge from most of the vaccinated dogs. The challenge strain was shed in the dogs vaccinated with the lowest dose (10(6.0) cfu/dose) for two to three weeks but the other vaccinated groups (10(7.0) and 10(8.0) cfu/dose) shed the challenge strain transiently or not at all. Only the group vaccinated with 10(6.0) cfu/dose exhibited clinical signs after challenge.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/20023279/